Cardiac Effects Of Glp-1 Analogues

The aim of this review is to summarize the literature from in vitro, in vivo and human studies on the effects of GLP-1 analogues on the cardiovascular system, focusing on their impact on the inflammatory mechanisms implicated in the development of atherosclerosis.

GLP-1 receptor agonists were initially developed to treat type 2 diabetes and have had a transformative effect on its therapy, and are highly effective for glycaemic control, with the added benefit of bodyweight reduction and a low risk of causing hypoglycaemia. GLP-1 receptor agonists reduce risks for major adverse cardiovascular events (eg, non-fatal myocardial infarction, stroke, and ...

One mechanism is the reduction of oxidative stress and inflammation through the activation of the GLP-1 receptor in cardiac tissues. GLP-1 analogues also decrease apoptosis of cardiac cells and improve endothelial function, thereby contributing to the protection of the heart against cardiovascular diseases.

Such details provide a deeper understanding and appreciation for Cardiac Effects Of Glp-1 Analogues.

Protective effect of GLP-1 analogues on the risk of right heart failure in diabetic patients with PAH.

Exendin-4, an analog of glucagon-like peptide (GLP)-1, has beneficial effects on cardiovascular disease induced by diabetes mellitus (DM).

The potential therapeutic role of GLP-1 analogues, particularly exendin-4, is explored in addressing ductopenia associated with cholangiopathies, such as primary biliary cirrhosis and primary sclerosing cholangitis.